FDAnews
www.fdanews.com/articles/73650-alkermes-cephalon-to-share-drug-profit

ALKERMES, CEPHALON TO SHARE DRUG PROFIT

June 26, 2005

Alkermes has agreed with Cephalon to share future profits of Vivitrex, an investigational drug to treat alcohol dependence. Under the agreement, Cephalon and Alkermes will jointly develop and market the drug. Cephalon will pay Alkermes $160 million cash, plus $110 million if Vivitrex is approved by the FDA. Alkermes submitted its new drug application to the FDA in March and said the agency has granted Vivitrex priority review. On top of the $270 million, Cephalon may pay Alkermes $220 million in milestone fees, if the drug hits certain agreed-upon sales levels.

Forbes (http://www.forbes.com/smallbusiness/feeds/ap/2005/06/24/ap2110148.html)